- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made).
3.—(1) Regulation 2(1)(1) is amended as follows.
(2) For the definition of “Commission Directive 2003/94/EC” substitute—
““Commission Directive 2003/94/EC” means—
Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice for medicinal products for human use and for investigational medicinal products for human use, as modified by Schedule 2A to the 2012 Regulations(2), or
if Regulations have been made under the powers in regulation B17(1) of the 2012 Regulations(3), and have come into force, those Regulations;”.
(3) After the definition of “container” insert—
““country” means a country or territory;”.
(4) In the definition of “export”, for “a third country from an EEA State” substitute “another country from the United Kingdom”.
(5) Omit the definition of “the GCP Directive”.
(6) For the definition of “import” substitute—
““import” means import into the United Kingdom, whether by land, sea or air;”.
(7) In the definition of “investigational medicinal product”, before “marketing authorization” insert “UK”.
(8) For the definition of “marketing authorization”, substitute—
““marketing authorization” means—
a UK marketing authorization, or
an authorization granted by a regulatory body responsible for licensing medicinal products in a country that is included in the list referred to in regulation 2A(1);”.
(9) In the definition of “non-interventional trial”, before “marketing authorization”, insert “UK”.
(10) Omit the definition of “third country”.
(11) After the definition of “trial site” insert—
““UK marketing authorization” means—
a marketing authorisation granted by the licensing authority under the 2012 Regulations, or
a product licence granted by the licensing authority for the purposes of section 7 of the Medicines Act 1968;”.
(12) In the definition of “unexpected adverse reaction”, in paragraph (a), after “summary of product characteristics” insert “, or equivalent document,”.
Regulation 2(1) was amended by S.I. 2004/3224, 2005/2759, 2006/562 and 1928, 2007/3101, 2008/941, 2011/2581, 2012/1479, 1641 and 1916, 2013/235 and 2016/696 and S.R. 2008/192.
Schedule 2A is inserted by the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019.
Regulation B17 is inserted by the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: